Triple-negative breast cancer (TNBC) accounts for 10 to 20% of all invasive breast cancer (BrCa) cases and lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) responsiveness. This evidence concerns the gene PGR and invasive breast carcinoma.